Table 3.
MAb/PAba |
Relative antibody discriminating specificity (RADS) valuec |
||||||||
---|---|---|---|---|---|---|---|---|---|
Peptide/epitope on DENV-2 NS1 glycoprotein and sequence positionb | |||||||||
N-TM |
LD2 |
24A |
N'LX1 |
LX1 |
LX2/1 |
LX2/2 |
24 C |
LX2/3 |
|
5-15 | 25-33 | 61-69 | 109-117 | 113-121 | 209-217 | 267-275 | 301-309 | 331-339 | |
MAb |
|
|
|
|
|
|
|
|
|
1H7.4 |
* |
16.8 |
* |
* |
* |
* |
* |
* |
* |
5H4.3 |
* |
* |
4.2 |
* |
* |
* |
* |
* |
* |
3D1.4 |
* |
* |
* |
* |
15.0 |
* |
* |
* |
* |
1G5.3 |
* |
* |
* |
* |
* |
* |
* |
12.4 |
* |
1C6.3 |
1.12 |
1.05 |
0.47 |
0.93 |
* |
0.82 |
1.12 |
* |
1.67 |
1G5.4-A1-C3 |
1.10 |
0.88 |
0.62 |
1.26 |
* |
* |
* |
* |
0.97 |
PAb |
|
|
|
|
|
|
|
|
|
C57BL |
1.55 |
1.52 |
2.28 |
1.26 |
3.11 |
0.89 |
0.94 |
1.59 |
1.07 |
B10.S |
1.59 |
* |
2.40 |
1.64 |
2.77 |
0.57 |
0.77 |
1.58 |
0.64 |
B10.RIII |
1.44 |
1.46 |
1.52 |
1.24 |
* |
0.90 |
0.96 |
* |
1.02 |
B10.G |
1.27 |
1.07 |
* |
1.10 |
* |
0.98 |
0.93 |
1.18 |
0.87 |
B10.BR |
1.56 |
2.65 |
* |
1.15 |
* |
0.63 |
0.93 |
* |
1.35 |
B10.D2N |
1.37 |
1.33 |
* |
1.09 |
* |
* |
1.26 |
* |
1.23 |
B10.A | 1.24 | 1.33 | * | * | 1.08 | 1.11 | * | * | * |
aMonoclonal antibody (MAb) name or polyclonal antibody (PAb) pools from congeneic mouse strains (C57BL, B10.S, B10.RIII, B10.BR, B10.D2N and B10.A) generated against the DENV-2 NS1 glycoprotein.
bName of epitope defined by MAb 1H7.4, 5H4.3, 3D1.4 or 1G5.3 or peptide name identified by MAb 1G5.4-A1-C3 and/or 1C6.3 through their reactions with their ELK/KLE-type or KELK/KLEK-type motifs on the DENV-2 NS1 glycoprotein with their amino acid sequence location (N-TM = peptide N-TERM).
cRelative antibody discriminating specificity (RADS) value, determined from the average ELISA absorbance values of the MAbs or mouse PAb pools against synthetic peptides prepared in the natural/reverse orientations (fold difference of absorbance against the natural orientated peptide sequence/reverse orientated peptide sequence). MAb and PAb RADS values were only determined when they had absorbance (Abs) values of ≥ 0.650 against the peptide prepared in the natural orientation. RADS values of ≥ 1.50-fold or ≥ 2.50-fold are underlined and shown in bold, respectively. Reactions that were Abs < 0.650 against the peptide sequence prepared in the natural orientation are shown by asterixes.